BALVERSA ™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news